Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 13/20 | 0.48 |
| ▸ | EGFR | P00533 | 9/20 | 0.48 |
| ▸ | SRC | P12931 | 10/20 | 0.47 |
| ▸ | ABL1 | P00519 | 9/20 | 0.47 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.47 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 3/20 | 0.47 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.47 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.47 |
| ▸ | KIT | P10721 | 3/20 | 0.46 |
| ▸ | WEE1 | P30291 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14573081 | 0.87 | WEE1 (0.56) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL5583802 | 0.82 | ABL1 (0.61) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL5583794 | 0.82 | EGFR (0.50) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL5583903 | 0.81 | FGFR1 (0.55) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL5583963 | 0.81 | SRC (0.66) | FGFR1SRCABL1PDGFRBPDGFRA | |
| SCHEMBL5583941 | 0.79 | SRC (0.63) | FGFR1EGFRSRCPDGFRBPDGFRA | |
| SCHEMBL5583940 | 0.78 | ABL1 (0.47) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL28562488 | 0.77 | RIPK2 (0.47) | FGFR1EGFRSRCABL1PDGFRB | |
| SCHEMBL5659367 | 0.74 | MEN1 (0.52) | FGFR1EGFRSRCPDGFRBPDGFRA | |
| SCHEMBL5657548 | 0.73 | FGFR1 (0.55) | FGFR1EGFRSRCABL1PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007529451-A | — | — | 2007-10-25 | — | — | JP | claimed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | claimed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | claimed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | claimed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | claimed |
| US-7189732-B2 | Pyrido[2,3-d]pyrimidine dichloro-phenyl derivatives | HOFFMAN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1727819-A1 | NOVEL DICHLORO-PHENYL-PYRIDO¬2,3-D|PYRIMIDINE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-12-06 | — | — | EP | disclosed |
| US-20060014765-A1 | Dichloro-phenyl derivatives | HOFFMANN-LA ROCHE INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005090344-A1 | NOVEL DICHLORO-PHENYL-PYRIDO [2,3-D] PYRIMIDINE DERIVATES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014765-A1 | Dichloro-phenyl derivatives | SRC, ABL1, LCK | FGFR1 145/4885EGFR 114/4885SRC 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.